Investment Rating - The report maintains a "Buy" rating for Xiaomi Group-W (01810.HK) [1] Core Views - The company continues to focus on the "people, vehicles, and home" ecosystem, launching new products such as the YU7 SUV and the Xuanjie chips, which are expected to drive growth [7] - The YU7 SUV is positioned as a high-performance luxury vehicle with impressive specifications, including a maximum horsepower of 690 PS and a range of 835 km, which is the highest for mid-to-large electric SUVs [7] - The self-developed Xuanjie O1 chip marks Xiaomi as the fourth company globally to design a 3nm process mobile SoC, enhancing its product capabilities [7] - The company is expanding its high-end product offerings, with a 15.7% year-on-year increase in total smartphone shipments in 2024, and a 3% increase in the domestic high-end smartphone market share [7] Financial Projections - Total revenue is projected to grow from CNY 270.97 billion in 2023 to CNY 691.16 billion by 2027, with a compound annual growth rate (CAGR) of 13.62% [1] - Net profit attributable to shareholders is expected to increase significantly from CNY 17.48 billion in 2023 to CNY 59.31 billion in 2027, reflecting a CAGR of 26.93% [1] - The earnings per share (EPS) is forecasted to rise from CNY 0.67 in 2023 to CNY 2.29 in 2027 [1] - The price-to-earnings (P/E) ratio is projected to decrease from 73.19 in 2023 to 21.56 in 2027, indicating improving valuation [1] Market Position - Xiaomi's market capitalization is approximately CNY 1,043.39 million, with a closing price of HKD 53.00 [5] - The company has a price-to-book (P/B) ratio of 6.47 and a debt-to-asset ratio of 53.07% [6] - The company aims to expand its retail presence internationally, planning to open around 10,000 new Xiaomi stores overseas in the next five years [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is focusing on steady progress and active advancement, with a strong emphasis on optimizing its operational model and expanding its store network [8] - The "Red Pomegranate" plan has shown positive results, with the company successfully incubating new brands and expanding its market presence [8] - The company is leveraging digital upgrades and supply chain optimization to enhance customer satisfaction and operational efficiency [8] Financial Projections - Total revenue is projected to grow from 41,622 million in 2023 to 47,244 million by 2027, with a compound annual growth rate (CAGR) of approximately 3.62% [1] - Net profit attributable to shareholders is expected to increase from 4,499 million in 2023 to 5,269 million by 2027, reflecting a CAGR of about 4.77% [1] - The earnings per share (EPS) is forecasted to rise from 0.81 in 2023 to 0.95 by 2027, indicating a steady growth trajectory [1] Operational Strategy - The company is implementing a bottom-up site selection mechanism and strict standards for franchisee entry, focusing on product, scene, and management optimization [8] - The company has initiated a franchise model with a rigorous selection process, ensuring quality and standardization across its outlets [8] - The company has launched multiple new restaurant brands under the "Red Pomegranate" initiative, aiming to create a second growth curve [8] Digital and Supply Chain Enhancements - The company is utilizing big data and AI technologies to improve customer feedback processing and enhance service quality [8] - The proprietary "HiHi System" app has achieved over 20,000 monthly clicks, indicating strong user engagement [8] - The deployment of over 50 AI robots across various operational areas is aimed at improving efficiency and customer service [8]

证券研究报告·行业跟踪周报·医药生物 医药生物行业跟踪周报 国产创新药闪耀 ASCO 国际舞台 2025 年 05 月 25 日 增持（维持） [Table_Tag] [Table_Summary] 投资要点 证券分析师 朱国广 执业证书：S0600520070004 zhugg@dwzq.com.cn 行业走势 -18% -15% -12% -9% -6% -3% 0% 3% 6% 9% 12% 15% 2024/5/27 2024/9/24 2025/1/22 2025/5/22 医药生物 沪深300 相关研究 《三抗药物研发进入快车道，建议关 注泽璟制药、三生制药等》 2025-05-18 | 1. 本周及年初至今各医药股收益情况 4 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2. 中国创新药闪耀 ASCO 会议，口头报告数量再创新高 7 | | | | | | | | | 2.1. 2025 ASCO 摘要披露，众多国产抗体和 ADC 类分子亮相口头报告 7 | | | | | | | | | 后线治疗不断迎 ...

证券研究报告·行业跟踪周报·建筑材料 建筑材料行业跟踪周报 继续推荐消费建材 2025 年 05 月 25 日 增持（维持） [Table_Tag] [Table_Summary] 投资要点 证券分析师 黄诗涛 执业证书：S0600521120004 huangshitao@dwzq.com.cn 证券分析师 房大磊 执业证书：S0600522100001 fangdl@dwzq.com.cn 证券分析师 石峰源 执业证书：S0600521120001 shify@dwzq.com.cn 行业走势 -26% -22% -18% -14% -10% -6% -2% 2% 6% 10% 14% 2024/5/27 2024/9/24 2025/1/22 2025/5/22 建筑材料 沪深300 相关研究 《期待服务消费加速》 2025-05-18 《 2024 年年报及 2025 年一季报综 述：需求继续承压，行业竞争出现缓 和信号》 2025-05-14 东吴证券研究所 1 / 21 请务必阅读正文之后的免责声明部分 ◼ 本周（2025.5.19–2025.5.23，下同）：本周建筑材料板块（SW）涨跌幅- 1 ...

证券研究报告·行业跟踪周报·建筑装饰 建筑装饰行业跟踪周报 基建投资保持平稳，关注水利、洁净室等 专业工程领域 增持（维持） [Table_Tag] [投资要点 Table_Summary] （2）出海方向：2025 年前 4 个月我国对外承包工程完成营业额 471.1 亿美元，同比增长 6.8%；新签合同额 765.9亿美元，同比增长 22.4%； 其中在共建"一带一路"国家新签合同额 645.4 亿美元，同比增长 17.4%；美国关税摩擦和全球贸易摩擦升级，后续外交博弈、贸易摩擦 或加剧，一带一路战略推进或加码，预期未来中欧合作、东盟地区合 作有望更加密切，基建合作仍是重要形式，海外工程需求景气度有望 保持，海外工程业务有望受益，后续预计逐渐兑现到订单和业绩层 面。建议关注国际工程板块，个股推荐中材国际、上海港湾，建议关 注中工国际、北方国际、中钢国际等。 执业证书：S0600521120001 shify@dwzq.com.cn 行业走势 （3）需求结构有亮点，新业务增量开拓下的投资机会：部分专业制造 工程细分领域、节能降碳以及新能源相关的基建细分领域景气度较 高，有相关转型布局的企业有望受益，建议关注 ...

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1] Core Insights - The A-share pharmaceutical index has increased by 1.8% this week and 4.3% year-to-date, outperforming the CSI 300 by 1.9% and 5.6% respectively [3][8] - The H-share biotechnology index has seen a rise of 6.7% this week and 36.4% year-to-date, outperforming the Hang Seng Technology Index by -7.4% and 19% [3][8] - The report highlights a significant increase in the number of domestic innovative drugs presented at the ASCO conference, with 25 oral presentations and 24 rapid oral presentations, marking a new high [14] Summary by Sections Industry Performance - A-share raw materials (+4.0%), chemical drugs (+3.6%), biological products (+1.7%), medical services (+1.4%), and pharmaceutical commerce (+1.2%) have shown notable price increases, while medical devices (+0.5%) and traditional Chinese medicine (+0.2%) have seen smaller gains [3][8] - Top performers in A-shares this week include Shengguojian (+100%), Haichen Pharmaceutical (+52%), and Shutaishen (+49%), while the largest declines were seen in Xin Ganjiang (-12%), Gongdong Medical (-10%), and Jinhao Medical (-9%) [3][8] R&D Developments - The report notes significant advancements in the development of innovative drugs, particularly in antibody and ADC molecules, with several companies like China Biopharmaceuticals and Innovent Biologics showcasing promising clinical data [14] - GlaxoSmithKline's IL-5 monoclonal antibody has been approved for treating COPD, marking a milestone as the first IL-5 drug approved for this indication [3] Investment Recommendations - The report suggests a ranking of favored sub-industries: innovative drugs > CXO > traditional Chinese medicine > medical devices > pharmacies > pharmaceutical commerce [9] - Recommended stocks based on growth potential include BeiGene, Hengrui Medicine, and Innovent Biologics, while undervalued stocks in traditional Chinese medicine include Zhaoli Pharmaceutical and Dong'e Ejiao [9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a net operating revenue of 13.8 billion yuan in Q1 2025, representing a year-on-year growth of 16%, in line with Bloomberg consensus expectations. The adjusted EBITDA was 4.2 billion yuan, with an EBITDA margin of 30%. The Non-GAAP net profit was 4.2 billion yuan, showing a year-on-year increase of 3%, which is better than Bloomberg consensus expectations [7] - The international business continues to grow significantly, with outbound travel maintaining stable growth. The cross-border flight capacity has recovered to 83% of pre-pandemic levels, and hotel and flight bookings for outbound travel have exceeded 120% of the same period in 2019, outperforming the market by 30%-40% [7] - Domestic tourism demand remains strong, with inbound tourism also experiencing robust growth. In Q1, the number of inbound travelers increased by 40% year-on-year, with 75% coming from visa-free regions. The company's platform saw a nearly 100% year-on-year increase in inbound bookings, with hotel bookings in major visa-free countries in the Asia-Pacific region surging over 240% [7] - The company continues to focus on enhancing its international business through better product experiences and customer service, with a sales expense ratio of approximately 21% in Q1, which is better than expected [7] - The profit forecast for 2025-2027 has been adjusted, with the adjusted net profit for 2025, 2026, and 2027 projected at 17.6 billion, 19.7 billion, and 22 billion yuan respectively, corresponding to P/E ratios of 18, 16, and 15 times [7] Financial Summary - Total revenue for 2023 is projected at 44.51 billion yuan, with a year-on-year growth of 122.12%. For 2024, revenue is expected to reach 53.29 billion yuan, reflecting a growth of 19.73% [1] - The company's net profit attributable to shareholders for 2023 is estimated at 9.92 billion yuan, with a staggering year-on-year growth of 606.91%. The forecast for 2024 is 17.07 billion yuan, indicating a growth of 72.08% [1] - The latest diluted EPS for 2023 is projected at 13.90 yuan per share, with a P/E ratio of 32.27 times [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a net operating revenue of 13.8 billion yuan in Q1 2025, representing a year-on-year growth of 16%, in line with Bloomberg consensus expectations. The adjusted EBITDA was 4.2 billion yuan, with an EBITDA margin of 30%. The Non-GAAP net profit was 4.2 billion yuan, showing a year-on-year increase of 3%, which is better than Bloomberg consensus expectations [7] - The international business continues to grow significantly, with outbound travel maintaining stable growth. The cross-border flight capacity has recovered to 83% of pre-pandemic levels, and hotel and flight bookings for outbound travel have exceeded 120% of the same period in 2019, outperforming the market by 30%-40% [7] - Domestic tourism demand remains strong, with inbound tourism also experiencing robust growth. In Q1, the number of inbound travelers increased by 40% year-on-year, with 75% coming from visa-free regions. The company's platform saw a nearly 100% year-on-year increase in inbound bookings, with hotel bookings in major visa-free countries in the Asia-Pacific region surging over 240% [7] - The company continues to focus on enhancing its international business through better product experiences and customer service, with a sales expense ratio of approximately 21% in Q1, which is better than expected [7] - The profit forecast for 2025-2027 has been adjusted, with the adjusted net profit for 2025, 2026, and 2027 projected at 17.6 billion, 19.7 billion, and 22 billion yuan respectively, corresponding to P/E ratios of 18, 16, and 15 times [7] Financial Summary - Total revenue for 2023 is projected at 44.51 billion yuan, with a year-on-year growth of 122.12%. For 2024, revenue is expected to reach 53.29 billion yuan, reflecting a growth of 19.73% [1] - The company's net profit attributable to shareholders for 2023 is estimated at 9.92 billion yuan, with a staggering year-on-year growth of 606.91%. The forecast for 2024 is 17.07 billion yuan, indicating a growth of 72.08% [1] - The latest diluted EPS for 2023 is projected at 13.90 yuan, with a P/E ratio of 32.27 times [1]

证券研究报告·行业跟踪周报·公用事业 公用事业行业跟踪周报 2025M1-4 月实现装机容量同比+15.9%、全 社会用电量+3.1% 增持（维持） [Table_Tag] [投资要点 Table_Summary ] ◼ 风险提示：需求不及预期、电价煤价波动风险、流域来水不及预期等 2025 年 05 月 25 日 证券分析师 袁理 执业证书：S0600511080001 021-60199782 yuanl@dwzq.com.cn 证券分析师 唐亚辉 执业证书：S0600520070005 tangyh@dwzq.com.cn 行业走势 -13% -10% -7% -4% -1% 2% 5% 8% 11% 14% 17% 2024/5/27 2024/9/24 2025/1/22 2025/5/22 公用事业 沪深300 相关研究 《广东 136 号文细则征求意见，增量 机制电量不超过 90%，海风/其他风电 /光伏分类竞价》 2025-05-20 《需求偏弱美国&国内气价回落，库 存同比偏低欧洲气价微增；对美 LNG 关税降至 25%》 2025-05-19 东吴证券研究所 1 / 21 请务必阅读正文之 ...

Investment Rating - The report maintains a positive outlook on the automotive sector, emphasizing the potential for growth driven by AI, robotics, and favorable market conditions [3]. Core Insights - The automotive sector is experiencing a mixed performance, with the SW automotive index up by 1.2% this week, while the commercial vehicle segment showed the highest increase at 9.4% [2][3]. - Key developments include BYD's new pricing strategies and significant revenue growth reported by companies like Xiaopeng Motors and Leap Motor [2][3]. - The report anticipates a strong demand for passenger vehicles in 2025, projecting a retail sales volume of 23.69 million units, a year-on-year increase of 4.1% [48][49]. Weekly Market Review - The total number of passenger vehicles insured this week was 381,000, reflecting a week-on-week decrease of 14% [47]. - The penetration rate of new energy vehicles reached 56.3%, with a total of 215,000 units sold [47]. - The report highlights the performance of specific stocks, with Jianghuai Automobile, Jingwei Hengrun, and Sai Lisi showing notable gains [2][3]. Industry Trends - The report identifies three main investment themes for 2025: AI robotics, AI intelligence, and favorable market conditions [3]. - The report predicts that L3 autonomous driving technology will see significant adoption, with a penetration rate of 27% among new energy vehicles by 2025 [51]. - The heavy truck segment is expected to see a 16.3% year-on-year increase in insurance volume, driven by domestic demand and supportive policies [53]. Company Performance - Xiaopeng Motors reported Q1 revenue of 15.81 billion yuan, a year-on-year increase of 141.5%, despite a slight quarter-on-quarter decline [2][3]. - Leap Motor's Q1 revenue reached 10.02 billion yuan, reflecting a year-on-year growth of 187.1% [2][3]. - BYD has introduced significant discounts on its vehicles, with price reductions of up to 53,000 yuan for certain models [2][3].